CAMP4 Therapeutics Corporation CAMP 深 滬
已收盤 02-06 16:00:00 美东时间
3.84
+0.250
+6.96%
華盛通- 最 高3.98
- 今 開3.65
- 成交量 4.09万股
- 最 低 3.65
- 昨 收 3.59
- 總市值 1.99亿
- 52周最高 7.305
- 市盈率 靜 --
- 換手率 0.08%
- 52周最低 1.305
- 委 比 67.21%
- 總股本 5188.11万
- 歷史最高 12.30
- 量 比 0.60
- 振 幅 9.19%
- 歷史最低 0.40
- 每 手 1
- 風險率 1.54%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMP4 Therapeutics Corporation granted a non-qualified stock option for 8,000 shares to a new employee under Nasdaq Listing Rule 5635(c)(4). The option has a 10-year term and an exercise price of $5.78, vesting over four years with 25% after one year and the remainder in monthly installments. CAMP4 focuses on RNA-targeting therapeutics to address genetic diseases by amplifying healthy protein levels.
01-16 21:05
CAMP4 Therapeutics updates corporate investor presentation materials
An announcement from CAMP4 Therapeutics Corporation ( ($CAMP) ) is now availabl...
01-10 06:04
CAMP4 Therapeutics Prices $30M Underwritten Offering Of 5M Shares At $6.00 Each
CAMP4 Therapeutics Corporation ("CAMP4" or the "Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression
2025-12-18 20:11
CAMP4 Therapeutics Enters Into Strategic Research, Collaboration And License Agreement With GSK To Identify, Develop ASO Drug Candidates For Multiple Gene Targets Relevant To Neurodegenerative And Kidney Disease Indications
Collaboration to leverage CAMP4's RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseasesCAMP4 to receive $17.5 million upfront and eligible forCollaboration to leverage CAMP4's RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseases
2025-12-18 20:03
CAMP4 Therapeutics shares are trading lower. The company reported Q3 financial results.
CAMP4 Therapeutics shares are trading lower. The company reported Q3 financial ...
2025-11-08 00:20
Camp4 Therapeutics Q3 EPS $(0.55) Beats $(0.68) Estimate, Sales $795.000K Beat $480.000K Estimate
Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.68) by 19.59 percent. This is a 97.73 percent increase over losses of $(24.19) per share
2025-11-07 05:35
美股大行评级 | 潜在涨幅216.96%！Kazia Therapeutics获Maxim Group升目标价至20美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Kazia Therapeutics"买入"评级，目标价从15美元升至20美元；Baird：维持Taysha Gene Therapies"跑赢大市"评级，目标价从7美元升至12美元
2025-10-03 14:32
Cantor Fitzgerald Initiates Coverage On Camp4 Therapeutics with Overweight Rating, Announces Price Target of $7
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Overweight rating and announces Price Target of $7.
2025-10-02 20:38
CAMP4 Initiates GLP Toxicology Studies for CMP-SYNGAP-01
CAMP4 Therapeutics Corporation ( ($CAMP) ) has provided an update. On October 1...
2025-10-01 20:48
JP Morgan Downgrades Camp4 Therapeutics to Neutral
JP Morgan analyst Anupam Rama downgrades Camp4 Therapeutics (NASDAQ:CAMP) from Overweight to Neutral.
2025-09-16 18:41
